Pharmacological approach to diabetic retinopathy.
Diabetic retinopathy is the most frequent cause of legal blindness in the population of 30-to-70-year olds. Whether retinopathy appears or not depends mainly on the duration of the disease and the degree of metabolic control the patient maintains. High blood glucose values lead to important changes in cellular metabolism and the main effects of these alterations are endothelial dysfunction that sets in motion the morphological process of diabetic retinopathy. The biochemical lesions caused by prolonged hyperglycemia can be positively influenced, but usually not normalized, pharmacologically with some groups of drugs, which are now under development. This makes tight control of glycemia a key measure in preventing the onset or progression of diabetic retinopathy, together with an effective program of ophthalmologic detection and follow-up in patients with diabetes. Regarding the role of endothelial dysfunction, antiplatelet drugs have been shown to slow some aspects of the evolution of diabetic retinopathy in its initial stages, mainly a lower degree of microaneurysms. However, a new approach to controlling endothelial dysfunction shows promise, mainly through the vascular endothelial growth factor (VEGF) inhibitors. These agents may prove to be especially useful in the treatment of proliferative diabetic retinopathy. Other encouraging results have been obtained in studies of antioxidant drugs and inhibitors of the formation of advanced glycation end products. Once retinal lesions appear, preventive measures need to be redoubled, with special attention to controlling glycemia; however, it is also necessary to resort to laser photocoagulation. This intervention aims to eliminate areas of ischemia and to diminish the formation of retinal exudates. If this measure fails or if vitreous hemorrhage appears, the only remaining therapeutic measure is vitrectomy.
De La Cruz
José Pedro
JP
Department of Pharmacology and Therapeutics, School of Medicine, University of Málaga, Málaga, Spain. jpcruz@uma.es
González-Correa
José Antonio
JA
Guerrero
Ana
A
de la Cuesta
Felipe Sánchez
FS
D000328:Adult; D000368:Aged; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology* / Q000601:surgery; D042783:Endothelial Cells / Q000201:enzymology* / Q000473:pathology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005123:Eye / Q000098:blood supply / Q000473:pathology; D006801:Humans; D006943:Hyperglycemia / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D017075:Laser Coagulation; D008875:Middle Aged; D013508:Ophthalmologic Surgical Procedures; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012160:Retina / Q000201:enzymology* / Q000473:pathology / Q000503:physiopathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D000975:Antioxidants; D001786:Blood Glucose; D004791:Enzyme Inhibitors; D010975:Platelet Aggregation Inhibitors; D042461:Vascular Endothelial Growth Factor A